Anixa Biosciences, Inc. (NASDAQ: ANIX), a California-based clinical-stage biotechnology company, announced on Thursday that it has added Sanjay Juneja, MD to its Cancer Business Advisory Board.
Dr Juneja, a board-certified haematologist and medical oncologist, is presently practicing in Baton Rouge, Louisiana. He has served on the White House Leaders in Social Media roundtable and has been featured by The Washington Post, CNBC, PBS, and WebMD, among many others. He serves as an editorial board member for the peer-reviewed research journal AI in Precision Oncology, and as a contributor to Entrepreneur Magazine.
Anixa chairman and CEO Dr Amit Kumar, said, 'Dr Juneja is an accomplished medical oncologist who has earned status as a top media personality on cancer prevention and treatment innovations. His influence has earned him invitations to help shape healthcare policy, and, most importantly, his public voice empowers cancer patients with knowledge, support, and hope. We anticipate that Sanjay's rapidly growing national profile will aid in educating the cancer community about the novelty of our vaccines and therapeutics. His broad reach will be beneficial to Anixa as we advance our programs, including enrolment and site recruitment for our current and upcoming clinical trials.'
Hemispherian's GLIX1 receives positive EU opinion for orphan designation in glioma
Arvinas and Pfizer submit FDA application for vepdegestrant in ESR1-mutated breast cancer
Alvotech and Dr. Reddy's collaborate on biosimilar candidate to cancer drug pembrolizumab
Aitia partners with Gustave Roussy in identifying fundamental biological causes of human cancers
Innovent's IBI363 granted second breakthrough therapy designation in China
Akeso's cadonilimab gains Chinese approval for first-line treatment of cervical cancer
Zynext Ventures invests in immuno-oncology company Agenus
IGI presents promising full dose-escalation results from Phase 1 study of ISB 2001
ImmuneOncia reports interim results from Phase 1b clinical trial of CD47 antibody
Innovent Biologics updates IBI343 data from Phase 1 clinical study in advanced pancreatic cancer
BioNTech and Bristol Myers Squibb partner to co-develop bispecific antibody for solid tumours
Leads Biolabs reports LBL-024 clinical data in advanced EP-NEC at 2025 ASCO
Johnson & Johnson reports first-in-human results for pasritamig in prostate cancer
Taiho Oncology and Cullinan Therapeutics report REZILIENT1 Phase 1/2 data